Waldemar Debinski | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Waldemar Debinski | Cancer Cell Biology | Best Researcher Award

Wake Forest School of Medicine | United States

Dr. Waldemar Debinski, M.D., Ph.D., is a distinguished neuroscientist and cancer researcher recognized for his pioneering work in brain tumor biology and targeted molecular therapies. His research focuses on understanding the molecular mechanisms that drive the development and progression of malignant brain tumors, with a particular emphasis on gliomas. Dr. Debinski has significantly contributed to the development of novel targeted therapeutics, including receptor-directed cytotoxins and biologics designed to selectively eliminate tumor cells while sparing healthy tissues. His investigations bridge molecular oncology, translational science, and clinical application, aiming to improve therapeutic outcomes for patients with brain cancers. Throughout his career, he has integrated insights from physiology, molecular biology, and pharmacology to develop translational approaches that move from laboratory discovery to clinical implementation. His extensive research has advanced the understanding of tumor-specific receptors and intracellular signaling pathways, contributing to innovative strategies in cancer immunotherapy and precision medicine. Dr. Debinski’s work exemplifies the integration of basic and clinical research toward the development of next-generation treatments for central nervous system malignancies, positioning him as a leading figure in neuro-oncology and translational cancer research.

Profile: Scopus

Featured Publications:

Wocial, B., Januszewicz, W., Siedlecki, J., Feltynowski, T., & Debinski, W. (1982). Alterations in plasma dopamine-β-hydroxylase and catecholamine concentrations during surgical removal of pheochromocytoma. Endocrinologie, 79, 131–139.

Debinski, W., & Wocial, B. (1982). Various aspects of sodium metabolism in hypertension [in Polish]. Polski Tygodnik Lekarski, 37, 1339–1342.

Ignatowska-Świtalska, H., Debinski, W., & Chojnowski, K. (1983). The role of certain hormonal factors in arterial hypertension [in Polish]. Materia Medica Polona, 15, 74–86.

Wasawska, T., Feltynowski, T., Majewska, Z., Januszewicz, W., Sobolewska-Karwowska, A., Wocial, B., & Debinski, W. (1984). Pheochromocytoma: Description of two cases with an unusual clinical picture [in Polish]. Polski Tygodnik Lekarski, 39, 261–263.

Czarkowski, M., & Debinski, W. (1984). Sodium and primary arterial hypertension [in Polish] (Review). Kardiologia Polska, 27, 967–976.

Wocial, B., Debinski, W., Jablonska-Skwicinska, E., Feltynowski, T., Chodakowska, J., Kozakowska, E., & Januszewicz, W. (1984). Sodium content of erythrocytes in patients with arterial hypertension [in Polish]. Polski Archiwum Medycyny Wewnetrznej, 72, 167–174.

Garcia, R., Debinski, W., Gutkowska, J., Kuchel, O., Thibault, G., Genest, J., & Cantin, M. (1985). Gluco- and mineralocorticoids may regulate the natriuretic effect and the synthesis and release of atrial natriuretic factor by the rat atria in vivo. Biochemical and Biophysical Research Communications, 131, 806–814.

Debinski, W., Kuchel, O., Garcia, R., Buu, N. T., Racz, K., Cantin, M., & Genest, J. (1986). Atrial natriuretic factor inhibits sympathetic activity in one-kidney, one-clip hypertension in the rat. Proceedings of the Society for Experimental Biology and Medicine, 181, 173–177.

Debinski, W., Kuchel, O., Buu, N. T., Garcia, R., Cantin, M., & Genest, J. (1986). Involvement of the adrenal glands in the action of the atrial natriuretic factor. Proceedings of the Society for Experimental Biology and Medicine, 181, 318–324.

Debinski, W., Gutkowska, J., Kuchel, O., Racz, K., Buu, N. T., Cantin, M., & Genest, J. (1986). ANF-like peptide(s) in the peripheral autonomic nervous system. Biochemical and Biophysical Research Communications, 134, 279–284.

Evgeny Deforzh | Cancer | Best Researcher Award

Published on by Cell Biologist

Dr. Evgeny Deforzh | Cancer | Best Researcher Award

Brigham and Women’s Hospital, Harvard University | United States

Dr. Evgeny Deforzh is a molecular biologist whose work focuses on the regulation of RNA, microRNAs, chromatin dynamics, and their roles in cancer and neurological disease. After earning his B.S. and M.S. in Biology from Saint Petersburg State University and a Ph.D. in Molecular Biology from Paris‑Saclay University, he completed postdoctoral research as a Research Fellow and subsequently served as Instructor in Neurology at Brigham & Women’s Hospital. His peer‑reviewed contributions include insights into how WEE1 regulators switch roles in cell cycle control, protection of cyclin mRNAs from translational repression, the impact of glioblastoma‑derived extracellular vesicles on astrocyte transformation, and the nuclear modulation of splicing by oncogenic microRNAs. More recently, his work has elucidated promoter/enhancer RNA regulation of super‑enhancers, and miRNA pathways as therapeutic targets in gliomas and meningiomas. To date, Dr. Deforzh has published ~15–20 independent original research articles (first‑, co‑first, or senior‑author) with many additional co‐authored papers. His publications have been cited in the literature ~800‑1,200 times, giving him an approximate h‑index of 12–15. His research has advanced understanding of RNA regulatory networks in cancer and offers potential translational pathways for diagnostics and therapy.

Profiles: Google Scholar | Scopus

Featured Publications:

Zeng, A., Wei, Z., Rabinovsky, R., Jun, H. J., El Fatimy, R., Deforzh, E., & Arora, R. (2020). Glioblastoma-derived extracellular vesicles facilitate transformation of astrocytes via reprogramming oncogenic metabolism. iScience, 23(8), 101420.

Deforzh, E., Uhlmann, E. J., Das, E., Galitsyna, A., Arora, R., Saravanan, H., … (2022). Promoter and enhancer RNAs regulate chromatin reorganization and activation of miR-10b/HOXD locus, and neoplastic transformation in glioma. Molecular Cell, 82(10), 1894–1908.e5.

El Fatimy, R., Zhang, Y., Deforzh, E., Ramadas, M., Saravanan, H., Wei, Z., … (2022). A nuclear function for an oncogenic microRNA as a modulator of snRNA and splicing. Molecular Cancer, 21(1), 17.

Poller, W., Sahoo, S., Hajjar, R., Landmesser, U., & Krichevsky, A. M. (2023). Exploration of the noncoding genome for human-specific therapeutic targets—Recent insights at molecular and cellular level. Cells, 12(22), 2660.

Deforzh, E., Vargas, T. R., Kropp, J., Vandamme, M., Pinna, G., & Polesskaya, A. (2016). IMP-3 protects the mRNAs of cyclins D1 and D3 from GW182/AGO2-dependent translational repression. International Journal of Oncology, 49(6), 2578–2588.

Kratassiouk, G., Pritchard, L. L., Cuvellier, S., Vislovukh, A., Meng, Q., … (2016). The WEE1 regulators CPEB1 and miR-15b switch from inhibitor to activators at G2/M. Cell Cycle, 15(5), 667–677.

Yavuz Tekelioğlu | Cancer Cell Biology | Best Academic Researcher Award

Published on by Cell Biologist

Prof. Dr. Yavuz Tekelioğlu | Cancer Cell Biology | Best Academic Researcher Award

Prof. Dr. Yavuz Tekelioğlu | Karadeniz Technical University | Turkey

Prof. Dr. Yavuz Tekelioğlu is a distinguished professor at Karadeniz Technical University’s Faculty of Medicine, specializing in histology, embryology, and toxicology. He has built a prolific academic career focused on cellular and tissue analysis using advanced methods like flow cytometry. Since beginning as a research assistant, he has steadily advanced through academic ranks, culminating in a full professorship. He has supervised numerous theses, contributing significantly to training future scientists. His research emphasizes the protective effects of antioxidants and stem cell therapies on tissue toxicity, with over 100 peer-reviewed publications. Active in professional societies, he also provides comprehensive educational instruction in medicine and dentistry. Prof. Tekelioğlu is committed to advancing biomedical research, particularly in reproductive and hepatic toxicology, through innovative experimental approaches.

Publication Profile:

Scopus

Education:

Prof. Dr. Yavuz Tekelioğlu completed his higher education at Karadeniz Technical University, where he earned his PhD after serving as a research assistant. His academic foundation is firmly rooted in medical sciences, with a focus on histology and embryology. During his doctoral studies, he developed expertise in experimental toxicology and cellular biology, particularly utilizing flow cytometry for immunophenotyping. His training includes specialized certifications in scientific research ethics, flow cytometry techniques, and institutional educational management. These credentials equip him to conduct rigorous, ethical research and provide effective academic leadership. Continuous participation in national and international workshops and symposiums reflects his commitment to staying current with cutting-edge methodologies and ethical standards in biomedical research.

Experience:

Starting as a research assistant, Prof. Tekelioğlu quickly advanced to PhD research assistant, assistant professor, associate professor, and finally full professor at Karadeniz Technical University. Over more than three decades, he has taught histology and embryology to medical, dental, and graduate students while supervising numerous theses on tissue toxicity and protective agents. He has led multiple TÜBİTAK and university-funded projects focusing on mesenchymal stem cells and toxicological evaluations using flow cytometry and histopathology. His academic service extends to practical flow cytometry training, contributing to capacity building in biomedical research. His administrative roles include coordinating research ethics training and educational management. He is a member of prominent scientific societies, contributing to Turkey’s scientific community. His career demonstrates dedication to both research and education.

Research Focus:

Prof. Dr. Tekelioğlu’s research primarily focuses on the histopathological and immunological effects of toxic agents on reproductive and hepatic tissues. His work extensively explores the protective roles of antioxidants like vitamin E, lycopene, beta-glucan, and Coenzyme Q10 against methotrexate-induced toxicity. Employing flow cytometry, histology, and biochemical assays, his studies provide mechanistic insights into cellular apoptosis, oxidative stress, and tissue regeneration. He investigates mesenchymal stem cells for their therapeutic potential in tissue repair and immunomodulation. His experimental models often include rats and mice, enabling controlled studies of drug-induced organ damage and protective interventions. By bridging toxicology with cellular analysis, his research contributes to safer clinical drug use and novel treatment strategies. Additionally, his recent work on ovarian and cardiac protection highlights translational relevance. His interdisciplinary approach combines toxicology, reproductive biology, and flow cytometry, establishing him as a leader in biomedical research.

Publication Top Notes: 

  • Coenzyme Q10 may protect ovarian tissue against methotrexate-induced gonadotoxicity: a biochemical, flow cytometric, and histopathological study

  • A Comparison of the Flow Cytometric Analysis Results of Benign and Malignant Serous Tumors of the Ovary

  • Should combined MTX and CoQ10 use be reconsidered in terms of steatosis? A biochemical, flow cytometry, histopathological experimental study

  • Histological and flow cytometric evaluation of astaxanthin’s effects against cyclophosphamide induced heart injury in rats

  •  Melamine exposure during the weaning period negatively affects ovarian reserve

Conclusion:

Prof. Dr. Yavuz Tekelioğlu is well-qualified and highly suitable for the Best Academic Researcher Award based on his extensive career, strong research leadership, significant scholarly contributions, and educational impact. His focused expertise on toxicology, histology, and cellular analysis is both relevant and impactful.

With strategic enhancements in international collaborations and visibility, he can further solidify his standing as a leading academic researcher. Nonetheless, his current achievements and dedication clearly merit recognition at this level.

Nives Jonjić | Cancer Cell Biology | Women Researcher Award

Published on by Cell Biologist

Prof. Dr. Nives Jonjić | Cancer Cell Biology | Women Researcher Award

Prof. Dr. Nives Jonjić | Department of Pathology and Citology, CHC Rijeka | Croatia

Prof. Nives Jonjić, MD, is a Full Professor Emeritus at the Department of General Pathology and Pathological Anatomy, Faculty of Medicine, University of Rijeka, Croatia. With a distinguished academic and clinical career spanning decades, Prof. Jonjić has made significant contributions to oncologic and molecular pathology. Her work focuses on understanding molecular markers in tumor progression and their diagnostic and prognostic relevance. As a prolific researcher and author, she has published extensively in high-impact international journals and collaborated with leading experts in pathology and oncology. Known for her diagnostic precision and dedication to academic mentorship, she has guided numerous medical students, residents, and doctoral candidates. Her legacy includes groundbreaking studies on biomarkers like Nectin-2 and Nectin-4 and rare pathologic entities. Prof. Jonjić’s leadership and scientific rigor make her a prominent figure in Croatian medical science and a respected name in international pathology circles.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. Extensive Academic and Clinical Experience
    Prof. Nives Jonjić is a Full Professor Emeritus in pathology with decades of clinical, academic, and research experience, making her a veteran in her field.

  2. Strong Research Track Record

    • Multiple first and co-authored papers in peer-reviewed journals such as Current Issues in Molecular Biology, Pathology Research and Practice, and Clinical Pathology.

    • A clear focus on oncologic pathology, including biomarkers (e.g., Nectin-2 and Nectin-4), angiogenesis, lymphomas, and myelomas.

  3. Mentorship and Academic Leadership
    She has played a key role in mentoring junior scientists, guiding doctoral research, and shaping curriculum and teaching in pathology at the University of Rijeka.

  4. Work on Rare and Challenging Diagnoses
    Her research includes diagnostic dilemmas and rare malignancies, showing depth and clinical relevance, such as CD20-negative B-cell lymphomas and extranodal Hodgkin lymphomas.

  5. Contribution to Women in Science
    As a senior female figure in medicine, her position as a full professor and mentor has made her a role model in advancing women’s participation in scientific leadership roles.

📉 Areas for Improvement:

  1. Broader International Visibility
    While her research is of high quality, greater engagement in global collaborative projects, EU-funded consortia, or as a keynote speaker in international forums could enhance her visibility outside Croatia.

  2. Higher Citation Metrics and Impact Index
    Although several of her publications are impactful, a few are recent and not yet widely cited. Participation in meta-analyses or review articles might help amplify her citation footprint.

  3. Digital and Social Research Presence
    A more proactive presence on platforms like ResearchGate, ORCID, or Google Scholar and involvement in open-access science movements could increase accessibility to her work.

🎓 Education:

Prof. Nives Jonjić completed her Medical Degree (MD) at the Faculty of Medicine, University of Rijeka, where she also pursued her postgraduate education and specialization in pathology. Her academic excellence was evident early in her medical training, leading to her progression into research and teaching. She earned her doctoral degree (PhD) with a focus on tumor biology and pathology. Over the years, she attended various advanced courses and workshops in Europe related to histopathology, immunohistochemistry, and oncologic diagnostics. Her commitment to continuous learning kept her updated with evolving trends in cancer research and molecular pathology. Through rigorous training and international collaborations, she established herself as a scholar deeply engaged with both clinical and experimental pathology. Her educational path reflects a deep integration of medical knowledge, critical inquiry, and a lifelong dedication to academic excellence.

🧪 Professional Experience:

Prof. Nives Jonjić has over 35 years of experience in academic medicine and pathology. Beginning as a junior lecturer and advancing through roles of Associate Professor and Full Professor, she served at the Faculty of Medicine, University of Rijeka, where she also led the Department of General Pathology and Pathological Anatomy. Her clinical practice included diagnostic histopathology with subspecialty interests in hematopathology, soft tissue tumors, and gynecologic oncology. She played a key role in curriculum development, faculty mentorship, and postgraduate training. As an expert pathologist, she consulted on complex diagnostic cases nationally and internationally. Beyond clinical and teaching roles, she has been a principal investigator and co-investigator in multiple research projects and has evaluated numerous PhD theses. Her rich experience spans clinical excellence, research leadership, and educational mentorship, making her a pillar in Croatian medical academia.

🏆 Awards and Honors:

Prof. Nives Jonjić has received numerous awards and accolades throughout her career for her contributions to medical research, education, and clinical pathology. Among her honors are institutional recognition for excellence in teaching from the University of Rijeka, national awards for research contributions, and commendations from Croatian medical societies. She has also been invited to deliver keynote lectures at international conferences and served as a peer reviewer for esteemed pathology journals. Her election as Full Professor Emeritus reflects the high regard in which she is held by her peers and institution. Prof. Jonjić has been actively involved in academic boards and ethical committees and received acknowledgments for advancing women’s leadership in medicine. Her work continues to inspire future generations of medical researchers and clinicians, and her accolades affirm her dedication to science, education, and healthcare.

🔬 Research Focus:

Prof. Jonjić’s research primarily focuses on tumor pathology, with special emphasis on the expression and role of molecular biomarkers such as Nectin-2, Nectin-4, osteopontin, and NF-κB in cancer progression, diagnosis, and prognosis. Her studies span various malignancies including squamous cell carcinomas, glial tumors, lymphomas, and multiple myeloma. She is also engaged in investigating rare and diagnostically challenging pathological conditions, contributing to more accurate clinical-pathologic correlations. Her recent research has emphasized angiogenesis, immune profiling, and the tumor microenvironment. She employs advanced histopathological and immunohistochemical techniques to support translational applications in pathology. Through collaboration with multidisciplinary teams, her work bridges laboratory findings with clinical decision-making. Her research is widely cited, reflecting its importance in improving diagnostic accuracy and treatment stratification in oncology. Prof. Jonjić’s academic leadership and focus on innovative diagnostic markers make her a central figure in Croatian cancer research.

📚 Publications Top Notes:

  1. 🗣️ Laryngeal Squamous Cell Carcinoma Is Characterized by a Stronger Expression of Nectin-4 Compared to Nectin-2

  2. 🧠 The Prognostic Significance of Nectin-2 and Nectin-4 Expression in Glial Tumors

  3. 💉 Anti-angiogenic Effect of Bortezomib Treatment in Multiple Myeloma Associated with Lower NF-κB and OPN Expression

  4. 🔬 Primary Nodal Unclassifiable CD20 Negative Diffuse Large B-cell Lymphoma With Dual IgK and TCR Gene Rearrangement

  5. 🦴 Angiogenesis and Osteopontin Expression in Paraskeletal Myeloma With Plasmablastic Morphology

  6. 🧪 Diagnostic Challenge of Soft Tissue Extranodal Hodgkin Lymphoma in Core-Needle Biopsy

  7. 💊 Lichen Planus Pigmentosus-like Reaction to Pirfenidone in Idiopathic Pulmonary Fibrosis

  8. 🦷 Recurrent Adamantinoma With Fibrous Dysplasia-like Feature

  9. 💉 Adalimumab as a Risk Factor for Development of Melanocytic Lesions

  10. 🧬 Expression Profiles of Metallothionein-I/II and Megalin/LRP-2 in Uterine Cervical Lesions

🏁 Conclusion:

Prof. Nives Jonjić is a highly suitable candidate for the Research for Women Researcher Award. Her scholarly contributions in pathology, especially tumor diagnostics and molecular markers, are significant and clinically relevant. Her work is anchored in academic integrity and mentorship, fostering the next generation of medical scientists. While global visibility could be enhanced, her regional impact, sustained productivity, and role as a senior academic make her a strong and deserving nominee.

 

Weifen Zhang | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Prof. Weifen Zhang | Cancer Cell Biology | Best Researcher Award

Prof. Weifen Zhang , Shandong Second Medical University , China

Professor Weifen Zhang is a renowned scientist in pharmaceutical sciences, serving as a Professor at the School of Pharmacy, Shandong Second Medical University. She also directs the Shandong Engineering Research Center for Intelligent Materials and Regenerative Medicine and the Pharmaceutical Experimental Teaching Center. With over 50 SCI-indexed publications and 27 national and international patents, her contributions have significantly influenced the development of targeted drug delivery systems and smart biomaterials. A recipient of the State Council Special Allowance and recognized as a Shandong Provincial Outstanding Expert, Professor Zhang combines academic excellence with practical innovation. She has led and collaborated on numerous national-level research projects, focusing on novel therapeutic strategies for cancer, regenerative medicine, and nano-drug technologies. Additionally, she plays a prominent role in scientific publishing as a guest editor and reviewer for leading journals. Her dedication to interdisciplinary research continues to shape the future of pharmaceutical technology.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. 📚 High Research Productivity: Over 50 SCI-indexed publications in high-impact journals such as ACS Applied Materials & Interfaces, Journal of Biomedical Nanotechnology, and Science China Materials.

  2. 💡 Innovation & Intellectual Property: Holds 27 national and international patents, showing a strong translation of academic work into real-world applications.

  3. 🔬 Research Focus & Impact: Cutting-edge work in targeted drug delivery systems, intelligent biomaterials, and regenerative medicine, especially impactful in oncology.

  4. 🎯 Project Leadership: Principal Investigator for multiple nationally funded projects, managing significant funding amounts and driving original discoveries.

  5. 🌐 Academic Influence: Serves as a guest editor and reviewer for leading scientific journals, contributing to quality control and peer knowledge advancement.

  6. 📖 Educational Impact: Contributions to national-level textbooks like Pharmaceutics and Pharmaceutical English highlight her role in shaping future pharmaceutical education.

  7. 🤝 Industry Collaboration: Active collaborations with companies like NOIMAIER (Shandong) Medical Technology Co., Ltd, demonstrating practical application and outreach.

⚠️ Areas for Improvement:

  1. 🌍 Global Outreach: While her influence is strong nationally, increased participation in international conferences, collaborations, and global visibility would further elevate her stature.

  2. 🎙️ Public Engagement: Enhanced involvement in science communication, including talks, public articles, or media, could broaden her societal impact.

  3. 🌐 Online Presence: A more visible online research profile (e.g., Google Scholar, ResearchGate, LinkedIn) could help in networking and research dissemination globally.

🎓 Education:

Professor Weifen Zhang received comprehensive training in pharmaceutical sciences, culminating in a doctorate in pharmacy or a related biomedical field (specific degree and institution not provided in the current profile). Her academic journey has been deeply rooted in advancing applied pharmaceutical research, especially in the field of drug delivery and intelligent materials. Her educational background laid the foundation for her specialization in nanoformulations, regenerative medicine, and drug resistance reversal. Professor Zhang has supplemented her academic credentials with continued professional development through her work with major national science foundations and governmental innovation programs. Her commitment to combining traditional pharmaceutical training with cutting-edge material science has enabled her to become a leader in translational research. Although the detailed degrees and institutions are not specified, her track record in high-impact research, publications, and academic leadership reflects a strong and diverse educational background.

🧪 Experience:

Professor Zhang brings over two decades of experience in pharmaceutical sciences, nanomedicine, and biomaterial engineering. She has served in multiple leadership roles, including Director of both the Shandong Engineering Research Center for Intelligent Materials and Regenerative Medicine and the Pharmaceutical Experimental Teaching Center at Shandong Second Medical University. As Principal Investigator on numerous high-profile projects funded by the National Natural Science Foundation of China and regional innovation programs, she has demonstrated excellence in both basic and translational research. Her industrial collaborations and consultancy projects, such as those with NOIMAIER Medical Technology, reflect her ability to translate scientific innovation into practical solutions. Her experience is also reflected in her active editorial and peer review contributions to top-tier journals, as well as her involvement in educational contributions through national textbook projects. Her academic, industrial, and clinical translational experiences make her a uniquely qualified and impactful researcher.

🔬 Research Focus:

Professor Weifen Zhang’s research is at the forefront of targeted drug delivery, intelligent biomaterials, and regenerative medicine. Her primary scientific focus involves developing novel nanoparticle-based platforms to improve therapeutic outcomes in diseases such as non-small cell lung cancer. She has led pioneering studies in dual-drug synergistic delivery, utilizing agents like quercetin and paclitaxel, aimed at overcoming drug resistance. Her lab also explores smart, biodegradable materials, such as Bletilla striata polysaccharide microneedles, for innovative therapeutic applications including hair regrowth and skin regeneration. In regenerative medicine, she is advancing bionic materials, such as mineralized collagen scaffolds, for orthopedic and dental use. Additionally, she works on plant-derived compounds, contributing to both pharmaceutical and agricultural solutions. Through interdisciplinary approaches, including nanotechnology, immunology, and pharmacokinetics, Professor Zhang’s work is positioned to influence both academic research and clinical practice. Her vision continues to shape the field of personalized and precision medicine.

📚 Publications Top Notes:

  1. 📌 Bletilla striata polysaccharide-based dissolving microneedle patch integrated with nanoparticles for promoting hair regrowth

  2. 🧱 Composite scaffolds based on egg membrane and eggshell-derived inorganic particles promote soft and hard tissue repair

  3. 💉 Efficient chemo-immunotherapy leveraging minimalist electrostatic complex nanoparticle as “in situ” vaccine integrated tumor ICD and immunoagonist

  4. 🌿 A Chinese drug-compatibility-based approach to purslane hydrogels for acute eczema therapy

  5. 🔬 Dynamic Covalent Bond-Based Nanoassembly of Curcumin to Enhance the Selective Photothermal Therapy for Tumor Treatment

  6. 🧵 Multifunctional Nanofiber Membranes Constructed by Microfluidic Blow-Spinning to Inhibit Scar Formation at Early Intervention Stage

  7. 📄 Corrigendum to “Synergistically enhanced cancer immunotherapy by combining protamine-based nanovaccine with PD-L1 gene silence nanoparticle”

  8. 💉 Minimalist “in situ” tumor vaccine leveraging versatile dendrimer nanoplatform coordinated ICD and immunoagonist for boosted chemoimmunotherapy

  9. 🧬 A minimalist cancer cell membrane-shielded biomimetic nanoparticle for nasopharyngeal carcinoma active-targeting therapy

  10. ⚗️ Biodegradable Manganese-Containing Mesoporous Silica Nanoparticles for Precisely Controlled Quercetin Delivery

 

📌 Conclusion:

Professor Weifen Zhang demonstrates exceptional qualifications for the Best Researcher Award. Her deep scientific contributions, robust patent portfolio, influential publications, and national leadership in pharmaceutical innovation mark her as a leader in biomedical research. With a few enhancements in global visibility and science communication, her already impressive profile could reach even greater heights.